Despite extensive research in the field of cancer in recent decades, the incidence and mortality from cancer continues to rise. In the postgenomic era, we have obtained a more complete understanding of the molecular alterations of cancer cells. This information explosion has opened up new avenues for molecular diagnosis, and targeted/personalized treatment of cancer. This new path has also provided the basis for huge capital investments in cancer field. Many startups and knowledge-based companies are now involved in translating the latest scientific findings into clinical practice in the form of diagnostic kits, drug production, and effective treatment strategies.
At CGC2023, efforts have been made to invite several scientific societies related to the field of cancer (bioinformatics, genetics, molecular cell, cancer, oncology, pharmacy) to provide the maximum participation of congressional audiences from various fields. In addition to presenting the latest scientific achievements in the field of cancer diagnosis and treatment, we intend to help start-ups and science-based companies to commercialize their ideas and products. In this holistic view, the congress provides an environment for health officials and policymakers, students, researchers, investors, startups, and knowledge-based companies to work together in a collaborative interactive space to expand knowledge and to find new ways to precise diagnose and effective treatment of cancer.
